RxDoctor Payments Data

Victor Liu

Boston, MANPI 1790279412

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (45.1%), travel and lodging and grants — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Abbott at 53.3% of the total. Reporting peaked in 2024 at $8,544 and has fallen 72.9% since, to $2,319 in 2025.

$19,893in general payments, 2019–2025

Across 161 payments — averaging $123.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$11K
  • Boston Scientific$4K
  • Medtronic$3K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$504
  • Philips North America LLC$487
  • Amgen$219
  • plus $1K from 12 others
$217in research payments, 2019–2025

Across 2 payments — averaging $108.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abiomed$217

What the payments were for

  • Grants$4,12621%
  • Travel & lodging$6,63533%
  • Food & beverage$8,97745%
  • Education$1541%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Metoprolol Succinate24$270
Carvedilol18$171
Atorvastatin Calcium11$107

Paid to pharmacies, not to this prescriber.

Where these figures come from

Is this you, or does something look wrong? →